ArticleRevista peruana de medicina experimental y salud publica2025
Resistance to colistin and fosfomycin in extended-spectrum beta-lactamase-producing Escherichia coli.
Article in Revista peruana de medicina experimental y salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of our study was to determine the resistance to colistin and fosfomycin of extended-spectrum beta-lactamase-producing Escherichia coli (Ec-BLEE). We conducted a cross-sectional descriptive study in which we analyzed 79 isolates of Ec-BLEE obtained from a previous study involving 300 chicken cloacal swab samples. We processed the isolates in the Microbiology and Immunology Laboratory of the Faculty of Medicine of the Universidad de Piura, Lima-Peru. We determined the sensitivity to colistin with the Colistin-AgarSpot detection medium and the sensitivity to fosfomycin by antibiogram according to the CLSI guidelines. We searched for the mcr-1 and fosA3 genes through PCR. We found a resistance to colistin in 17,7% and to fosfomycin in 77% of the samples. We did not detect the mcr-1 gene in the colistin-resistant isolates. The fosA3 gene was present in 100% of the fosfomycin resistant isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.